The Unintended Burden of Increased Prostate Cancer Detection Associated With Prostate Cancer Screening and Diagnosis

Urology

Volumn 75, Issue 2, 2010, Pages 399-405

  Albertsen, Peter C ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SCREENING; HEALTH STATUS; HUMAN; MENTAL HEALTH; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; RISK REDUCTION;

HUMANS; MALE; MASS SCREENING; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RISK FACTORS;

EID: 75349104313     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.08.078     Document Type: Review

References (49)

1. American Cancer Society. Cancer Facts and Figures 2007 (2007), American Cancer Society, Atlanta
2. Issa M.M., Fenter T.C., Black L., et al. An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. Am J Manag Care 12 (2006) S83-S89
3. Lilja H., Ulmert D., and Vickers A.J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 8 (2008) 268-278
4. American Urological Association. Prostate-specific antigen best practice statement: 2009 update (2009)
5. ACS, American Cancer Society. Guidelines for the Early Detection of Cancer (2008). http://www.cancer.org/docroot/PED/content/PED_2_3X_ACS_Cancer_Detection_Guidelines_36.asp Accessed July 2, 2008
6. USPSTF. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 149 (2008) 185-191
7. Albertsen P.C. PSA testing: public policy or private penchant?. J Am Med Assoc 296 (2006) 2371-2373
8. Bloch S., Love A., Macvean M., et al. Psychological adjustment of men with prostate cancer: a review of the literature. Biopsychosoc Med 1 (2007) 2
9. Andriole G.L., Crawford E.D., Grubb III R.L., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360 (2009) 1310-1319
10. Schroder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360 (2009) 1320-1328
11. Collin S.M., Martin R.M., Metcalfe C., et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 9 (2008) 445-452
12. Cooperberg M.R., Broering J.M., Kantoff P.W., et al. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 178 (2007) S14-S19
13. Andriole G.L., Levin D.L., Crawford E.D., et al. Prostate cancer screening in the prostate, lung, colorectal and ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 97 (2005) 433-438
14. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
15. Hernandez J., and Thompson I.M. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 101 (2004) 894-904
16. Fleming C., Wasson J.H., Albertsen P.C., et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. J Am Med Assoc 269 (1993) 2650-2658
17. Kattan M.W., Cowen M.E., and Miles B.J. A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med 12 (1997) 299-305
18. Dale W., Bilir P., Han M., et al. The role of anxiety in prostate carcinoma: a structured review of the literature. Cancer 104 (2005) 467-478
19. Korfage I.J., de Koning H.J., Roobol M., et al. Prostate cancer diagnosis: the impact on patients' mental health. Eur J Cancer 42 (2006) 165-170
20. Dall'Era M.A., Cooperberg M.R., Chan J.M., et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 112 (2008) 1650-1659
21. Martin R.M., Gunnell D., Hamdy F., et al. Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. J Urol 176 (2006) 439-449
22. Patel M.I., DeConcini D.T., Lopez-Corona E., et al. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 171 (2004) 1520-1524
23. Bacon C.G., Giovannucci E., Testa M., et al. The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients. Cancer 94 (2002) 862-871
24. Turini M., Redaelli A., Gramegna P., et al. Quality of life and economic considerations in the management of prostate cancer. Pharmacoeconomics 21 (2003) 527-541
25. Penson D.F. Quality of life after therapy for localized prostate cancer. Cancer J 13 (2007) 318-326
26. Stone P., Richards M., A'Hern R., et al. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol 11 (2000) 561-567
27. Truong P.T., Berthelet E., Lee J.C., et al. Prospective evaluation of the prevalence and severity of fatigue in patients with prostate cancer undergoing radical external beam radiotherapy and neoadjuvant hormone therapy. Can J Urol 13 (2006) 3139-3146
28. Albertsen P.C., Aaronson N.K., Muller M.J., et al. Health-related quality of life among patients with metastatic prostate cancer. Urology 49 (1997) 207-216 Discussion: 216-207
29. Litwin M.S., Lubeck D.P., Stoddard M.L., et al. Quality of life before death for men with prostate cancer: results from the CaPSURE database. J Urol 165 (2001) 871-875
30. Stewart S.T., Lenert L., Bhatnagar V., et al. Utilities for prostate cancer health states in men aged 60 and older. Med Care 43 (2005) 347-355
31. Clark J.A., Inui T.S., Silliman R.A., et al. Patients' perceptions of quality of life after treatment for early prostate cancer. J Clin Oncol 21 (2003) 3777-3784
32. Litwin M.S., Gore J.L., Kwan L., et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 109 (2007) 2239-2247
33. Hoffman R.M., Gilliland F.D., Penson D.F., et al. Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. Cancer 101 (2004) 2011-2019
34. Potosky A.L., Legler J., Albertsen P.C., et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the prostate cancer outcomes study. J Natl Cancer Inst 92 (2000) 1582-1592
35. Mantz C.A., Nautiyal J., Awan A., et al. Potency preservation following conformal radiotherapy for localized prostate cancer: impact of neoadjuvant androgen blockade, treatment technique, and patient-related factors. Cancer J Sci Am 5 (1999) 230-236
36. Bradley E.B., Bissonette E.A., and Theodorescu D. Determinants of long-term quality of life and voiding function of patients treated with radical prostatectomy or permanent brachytherapy for prostate cancer. BJU Int 94 (2004) 1003-1009
37. Buron C., Le Vu B., Cosset J.M., et al. Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study. Int J Radiat Oncol Biol Phys 67 (2007) 812-822
38. Weber B.A., Roberts B.L., Chumbler N.R., et al. Urinary, sexual, and bowel dysfunction and bother after radical prostatectomy. Urol Nurs 27 (2007) 527-533
39. Helgason A.R., Adolfsson J., Dickman P., et al. Waning sexual function-the most important disease-specific distress for patients with prostate cancer. Br J Cancer 73 (1996) 1417-1421
40. Gomella L.G. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues. BJU Int 99 Suppl 1 (2007) 25-29 Discussion: 30
41. Trask P.C. Quality of life and emotional distress in advanced prostate cancer survivors undergoing chemotherapy. Health Qual Life Outcomes 2 (2004) 37
42. Zeliadt S.B., Ramsey S.D., Penson D.F., et al. Why do men choose one treatment over another?. a review of patient decision making for localized prostate cancer. Cancer 106 (2006) 1865-1874
43. Northouse L.L., Mood D.W., Montie J.E., et al. Living with prostate cancer: patients' and spouses' psychosocial status and quality of life. J Clin Oncol 25 (2007) 4171-4177
44. Fleshner N., Gomella L.G., Cookson M.S., et al. Delay in the progression of low-risk prostate cancer: rationale and design of the reduction by dutasteride of clinical progression events in expectant management (REDEEM) trial. Contemp Clin Trials 28 (2007) 763-769
45. Thompson I.M. Chemoprevention of prostate cancer: agents and study designs. J Urol 178 (2007) S9-S13
46. Lippman S.M., Klein E.A., Goodman P.J., et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E Cancer Prevention Trial (SELECT). J Am Med Assoc 301 (2009) 39-51
47. Gaziano J.M., Glynn R.J., Christen W.G., et al. Vitamins E and C in the prevention of prostate and total cancer in men: the physicians' health study II randomized controlled trial. J Am Med Assoc 301 (2009) 52-62
48. Redman M.W., Tangen C.M., Goodman P.J., et al. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res 1 (2008) 174-181
49. Andriole G., Bostwick D., Brawley O., et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 172 (2004) 1314-1317